Targeting dendritic cells to advance cross-presentation and vaccination outcomes

IF 7.4 2区医学 Q1 IMMUNOLOGY

Seminars in Immunology Pub Date : 2023-07-01 DOI:10.1016/j.smim.2023.101762

Christophe Macri , Devi Jenika , Cassandra Ouslinis, Justine D. Mintern

{"title":"Targeting dendritic cells to advance cross-presentation and vaccination outcomes","authors":"Christophe Macri , Devi Jenika , Cassandra Ouslinis, Justine D. Mintern","doi":"10.1016/j.smim.2023.101762","DOIUrl":null,"url":null,"abstract":"<div><p>Dendritic cells (DCs) are a complex network of specialised antigen-presenting cells that are critical initiators of adaptive immunity. Targeting antigen directly to DCs in situ is a vaccination strategy that selectively delivers antigen to receptors expressed by DC subtypes. This approach exploits specific DC subset functions of antigen uptake and presentation. Here, we review DC-targeted vaccination strategies that are designed to elicit effective cross-presentation for CD8<sup>+</sup> T cell immunity. In particular, we focus on approaches that exploit receptors highly expressed by mouse and human cDCs equipped with superior cross-presentation capacity. These receptors include DEC205, Clec9A and XCR1. Targeting DC receptors Clec12A, Clec4A4 and mannose receptor is also reviewed. Outcomes of DC-targeted vaccination in mouse models through to human clinical trials is discussed. This is a promising new vaccination approach capable of directly targeting the cross-presentation pathway for prevention and treatment of tumours and infectious diseases.</p></div>","PeriodicalId":49546,"journal":{"name":"Seminars in Immunology","volume":"68 ","pages":"Article 101762"},"PeriodicalIF":7.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1044532323000532","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

Dendritic cells (DCs) are a complex network of specialised antigen-presenting cells that are critical initiators of adaptive immunity. Targeting antigen directly to DCs in situ is a vaccination strategy that selectively delivers antigen to receptors expressed by DC subtypes. This approach exploits specific DC subset functions of antigen uptake and presentation. Here, we review DC-targeted vaccination strategies that are designed to elicit effective cross-presentation for CD8⁺ T cell immunity. In particular, we focus on approaches that exploit receptors highly expressed by mouse and human cDCs equipped with superior cross-presentation capacity. These receptors include DEC205, Clec9A and XCR1. Targeting DC receptors Clec12A, Clec4A4 and mannose receptor is also reviewed. Outcomes of DC-targeted vaccination in mouse models through to human clinical trials is discussed. This is a promising new vaccination approach capable of directly targeting the cross-presentation pathway for prevention and treatment of tumours and infectious diseases.

查看原文本刊更多论文

靶向树突状细胞以促进交叉呈递和疫苗接种结果

树突状细胞（DC）是一个由专门的抗原呈递细胞组成的复杂网络，是适应性免疫的关键启动子。原位将抗原直接靶向DC是一种选择性地将抗原递送到DC亚型表达的受体的疫苗接种策略。这种方法利用了抗原摄取和呈递的特定DC亚群功能。在此，我们回顾了DC靶向疫苗接种策略，这些策略旨在引发CD8+T细胞免疫的有效交叉呈递。特别是，我们专注于利用由具有卓越交叉呈递能力的小鼠和人类cDC高度表达的受体的方法。这些受体包括DEC205、Clec9A和XCR1。还对靶向DC受体Clec12A、Clec4A4和甘露糖受体进行了综述。讨论了DC靶向疫苗接种在小鼠模型和人体临床试验中的结果。这是一种很有前途的新疫苗接种方法，能够直接针对交叉呈递途径预防和治疗肿瘤和传染病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Immunology 医学-免疫学

CiteScore

11.40

自引率

1.30%

发文量

审稿时长

89 days

期刊介绍： Seminars in Immunology is a specialized review journal that serves as a valuable resource for scientists in the field of immunology. The journal's approach is thematic, with each issue dedicated to a specific topic of significant interest to immunologists. It covers a wide range of research areas, from the molecular and cellular foundations of the immune response to the potential for its manipulation, highlighting recent advancements in these areas. Each thematic issue is curated by a guest editor, who is recognized as an expert in the field internationally. The content of each issue typically includes six to eight authoritative invited reviews, which delve into various aspects of the chosen topic. The goal of these reviews is to provide a comprehensive, coherent, and engaging overview of the subject matter, ensuring that the information is presented in a timely manner to maintain its relevance. The journal's commitment to quality and timeliness is further supported by its inclusion in the Scopus database, which is a leading abstract and citation database of peer-reviewed literature. Being indexed in Scopus helps to ensure that the journal's content is accessible to a broad audience of researchers and professionals in immunology and related fields.